Business Wire10.20.21
Medical imaging, robotics, and AI technology company Promaxo Inc. has appointed Theresa A. Matacia, CFA, as chief financial officer (CFO). With a mission to improve lives through state-of-the-art medical technology, Promaxo has made marked progress over the last year, recently receiving 510(k) clearance from the U.S. Food and Drug Administration for its Innovational MRI Platform.
“Theresa’s extensive experience and proven track record leading corporate financial strategies is a significant value add to Promaxo's development, as we strive to continue to expand our presence in the market,” said Dr. Amit Vohra, founder and CEO of Promaxo. “As an accomplished financial expert, particularly in B2B, Theresa will play an integral role in developing and implementing initiatives that will drive the company’s growth.”
Matacia’s record in business and Wall Street includes execution of transactions worth about $3 billion. Formerly with ADP, Scient Inc., and ADESA, Matacia will support the company’s vision and goals of creating a technological solution that will better patient lives and physicians’ abilities to treat cancers.
Matacia is a chartered financial analyst (CFA) and finance executive with deep experience in defining and implementing financial and operational strategies that support the CEO’s vision. With global industry expertise in B2B technology software/services, Matacia has a solid track record of sourcing, executing and completing M&A/IPO and capital raising transactions as well as multiple strategic alliances. After earning an MBA in finance, Matacia began a career on Wall Street as a sell-side equity analyst. During her 15-year tenure, she was widely recognized by large institutional investors for her financial and investment expertise in the business and technology software/services industries. An insightful industry expert, Matacia advised numerous senior management teams on strategy and positioning for their initial public offerings. Following her Wall Street career, Matacia led corporate finance and strategic initiatives for ADP, Scient, and ADESA, and has been CFO for a number of technology and other companies.
“As a chief financial officer, my passion has always been to elevate the potential of companies through strategic financial planning,” said Matacia. “My early career on Wall Street provided me the chance to become well-versed in the technology software and services industries, and I’m thrilled to be expanding this knowledge to the medical technology industry. I’m looking forward to working with the Promaxo team to grow the business and raise our profile in the medtech ecosystem.”
Recently, Promaxo raised a funding round led by Zepp Health. Promaxo is poised to improve the patient experience and enhance the in-office care continuum for physicians.
Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, Calif., and backed by over 90 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The company has formed numerous long-term and strategic partnerships with investor groups and corporations as it prepares to enter the U.S. market.
“Theresa’s extensive experience and proven track record leading corporate financial strategies is a significant value add to Promaxo's development, as we strive to continue to expand our presence in the market,” said Dr. Amit Vohra, founder and CEO of Promaxo. “As an accomplished financial expert, particularly in B2B, Theresa will play an integral role in developing and implementing initiatives that will drive the company’s growth.”
Matacia’s record in business and Wall Street includes execution of transactions worth about $3 billion. Formerly with ADP, Scient Inc., and ADESA, Matacia will support the company’s vision and goals of creating a technological solution that will better patient lives and physicians’ abilities to treat cancers.
Matacia is a chartered financial analyst (CFA) and finance executive with deep experience in defining and implementing financial and operational strategies that support the CEO’s vision. With global industry expertise in B2B technology software/services, Matacia has a solid track record of sourcing, executing and completing M&A/IPO and capital raising transactions as well as multiple strategic alliances. After earning an MBA in finance, Matacia began a career on Wall Street as a sell-side equity analyst. During her 15-year tenure, she was widely recognized by large institutional investors for her financial and investment expertise in the business and technology software/services industries. An insightful industry expert, Matacia advised numerous senior management teams on strategy and positioning for their initial public offerings. Following her Wall Street career, Matacia led corporate finance and strategic initiatives for ADP, Scient, and ADESA, and has been CFO for a number of technology and other companies.
“As a chief financial officer, my passion has always been to elevate the potential of companies through strategic financial planning,” said Matacia. “My early career on Wall Street provided me the chance to become well-versed in the technology software and services industries, and I’m thrilled to be expanding this knowledge to the medical technology industry. I’m looking forward to working with the Promaxo team to grow the business and raise our profile in the medtech ecosystem.”
Recently, Promaxo raised a funding round led by Zepp Health. Promaxo is poised to improve the patient experience and enhance the in-office care continuum for physicians.
Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, Calif., and backed by over 90 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The company has formed numerous long-term and strategic partnerships with investor groups and corporations as it prepares to enter the U.S. market.